Novan Therapeutics, a clinical stage biotech company focused on
advancing nitric oxide therapies, announced today that antiviral data
from a preclinical animal study has been accepted for presentation at
the 2014 Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC), taking place September 5-9, 2014, in Washington,
Presentation Number V-1822a: "Antiviral Efficacy of Nitric
Oxide-Releasing Drug Candidates In Vivo Utilizing the Cottontail Rabbit
Papillomavirus Model," K. Coggan, K. Balogh, S. Hollenbach, N.
Christensen, and N. Stasko
Presenter: Kimberly Coggan, PhD., Molecular Microbiolgist, Novan
Session Date, Time and Location: Monday, September 8, 2014; 11:00
a.m. - 1:00 p.m. EDT; Exhibit Hall B
About Novan, Inc.
Novan Therapeutics is a privately-held, clinical stage biotech company
focused on advancing nitric oxide therapies. Nitric oxide, one of the
most studied molecules in human physiology, has been shown to exhibit
antimicrobial activity and to promote vasodilation, regulate
inflammation, stimulate tissue repair, and eradicate cancer cells.
Novan's core technologies solve the previous delivery issues with nitric
oxide by stably storing the gaseous species on macromolecules that
result in a diverse pipeline of "timed-release" nitric oxide-releasing
new chemical entities. The company's proprietary platform technology
enables drugable nitric oxide in a variety of dosage forms.
To learn more about Novan Therapeutics, please visit www.novantherapeutics.com.
[ Back To NFVZone's Homepage ]